Abstract：【Objective】To investigate the efficacy of gemcitabine plus oxaliplatin (GEMOX) and gemcitabine plus cisplatin, dexamethasone (GDP) in the treatment of relapsed refractory non-Hodgkin's lymphoma(NHL). 【Methods】Retrospective analysis was conducted on a total of 80 cases of relapsed refractory NHL.. There were 40 patients who were treated with GEMOX regimen (A group) and 40 patients who were treated with GDP regimen (B group). Every cycle of treatment lasted 21 days. Efficacy, toxicity and Karnofsky scores were evaluated every two cycles of treatment.. 【Results】The total effective rates of patients with relapsed and refractory B-cell and T-cell lymphoma in group A were 62.96% (17/27) and 30.77% (4/13) respectively, significantly higher than those in group B (39.29%,11/28 and 16.67%,2/12) respectively (P<0.05); The incidence of nausea and vomiting in group Ⅲ~Ⅳ was significantly lower in group A than in group B (P<0.05). There was no significant difference in the other adverse reactions between the two groups (P>0.05). Karnofsky score decreased significantly after treatment in both groups, and Karnofsky score of the group B was significantly lower than that of the group A (P<0.05). 【Conclusion】The efficacy of GEMOX and GDP regimens in the treatment of relapsed and refractory B-cell lymphomas is significantly higher than that of T-cell lymphomas, and the short-term efficacy of GEMOX regimen in the treatment of relapsed and refractory NHL is significantly better than that of GDP. It is worthy of clinical promotion.
吴萍, 敬小梅, 余思思. GEMOX与GDP方案治疗复发难治性非霍奇金淋巴瘤的疗效比较[J]. 医学临床研究, 2018, 35(6): 1053-1055.
WU Ping, JIN Xiao-mei, YU Si-si. Clinical Efficacy of GEMOX and GDP Regimens in the Treatment of Relapsed Refractory Non-Hodgkin's Lymphoma. JOURNAL OF CLINICAL RESEARCH, 2018, 35(6): 1053-1055.
[1] 陈碧玲.吉西他滨联合奥沙利铂治疗淋巴瘤患者的疗效及安全性评[J].中国实验血液学杂志, 2015, 23(2):445-449.
[2] Friedberg JW. Relapsed/Refractory Diffuse Large B-Cell Lymphoma[J].Hematology Am Soc Hematol Educ Program,2011,2011:498-505.
[3] 王浩, 张晓波, 刘锋,等. GDP方案治疗复发和难治性非霍奇金淋巴瘤的疗效观察[J].实用癌症杂志, 2016, 31(4):668-669.
[4] 张玉碧.2周和3周的CHOP方案治疗非霍奇金淋巴瘤的临床研究[J].医学临床研究, 2007, 24(7):1179-1180.
[5] Raut LS.Management of realpsed-refractory diffuse large B cell lymphoma[J].South Asian J Cancer,2014,3(1):66-70.
[6] Patte C, Auperin A, Gerrard M,et al.Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients[J].Applied Soft Computing,2015, 27(C):158-168.
[7] 时杰, 孙恺, 张茵,等. 老年人难治弥漫大B细胞淋巴瘤不同挽救方案疗效分析[J].中华老年医学杂志, 2013, 32(2):184-187.
[8] 孙中义, 易平勇, 刘晰宇,等. ICE方案和GemOX方案治疗复发或难治性弥漫大B细胞淋巴瘤的临床观察[J].中国医师杂志, 2013, 15(2):242-244.
[9] 唐珂, 卢丽霞, 钟美佐. 利妥昔单抗联合化疗治疗HBsAg阳性的非霍奇金淋巴瘤患者的安全性分析[J].医学临床研究, 2015(5):1026-1028.
2018, Vol. 35 
